➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Express Scripts
Johnson and Johnson
Moodys
McKesson

Last Updated: August 13, 2020

DrugPatentWatch Database Preview

CAPECITABINE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Capecitabine patents expire, and what generic alternatives are available?

Capecitabine is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms, Eugia Pharma, Hikma, MSN, Mylan, Reliance Life, Shilpa Medicare Ltd, Sun Pharm, and Teva Pharms Usa. and is included in eleven NDAs.

The generic ingredient in CAPECITABINE is capecitabine. There are twenty-eight drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the capecitabine profile page.

US ANDA Litigation and Generic Entry Outlook for Capecitabine

A generic version of CAPECITABINE was approved as capecitabine by TEVA PHARMS USA on September 16th, 2013.

  Start Trial

Drug patent expirations by year for CAPECITABINE
Drug Prices for CAPECITABINE

See drug prices for CAPECITABINE

Recent Clinical Trials for CAPECITABINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
MedSIRPhase 2
ExelixisPhase 2
University of PennsylvaniaPhase 2

See all CAPECITABINE clinical trials

Pharmacology for CAPECITABINE
Medical Subject Heading (MeSH) Categories for CAPECITABINE
Paragraph IV (Patent) Challenges for CAPECITABINE
Tradename Dosage Ingredient NDA Submissiondate
XELODA TABLET;ORAL capecitabine 020896 2008-11-10

US Patents and Regulatory Information for CAPECITABINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare CAPECITABINE capecitabine TABLET;ORAL 202593-001 Apr 23, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Shilpa Medicare Ltd CAPECITABINE capecitabine TABLET;ORAL 207456-002 Dec 12, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
Eugia Pharma CAPECITABINE capecitabine TABLET;ORAL 210604-001 Apr 17, 2018 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Johnson and Johnson
Colorcon
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.